Description:
Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
- Molecular Weight: 415.432
- Molecular Formula: C22H18FN7O
Purity: > 95%
Canonical SMILES:
CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
InChI:
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
InChIKey: IFSDAJWBUCMOAH-HNNXBMFYSA-N
- Melting Point: 250-252°C
- Solubility: pH-dependent solubility ranging from <0.1 mg/mL at pH 5-7 to over 1 mg/mL at pH 2 under ambient conditions
- Appearance: Pale Brown Solid
- Application: the treatment of chronic lymphocytic leukemia (CLL)
Synonyms:
Idelalisib; CAL101; CAL 101; CAL-101; GS1101; GS 1101; GS-1101, Idelalisib.
More details are to be found on supplier website
